MacroGenics (MGNX)
(Delayed Data from NSDQ)
$4.14 USD
+0.40 (10.70%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $4.13 -0.01 (-0.24%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.14 USD
+0.40 (10.70%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $4.13 -0.01 (-0.24%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth D Momentum F VGM
Zacks News
MacroGenics (MGNX) Recently Broke Out Above the 20-Day Moving Average
by Zacks Equity Research
Should investors be excited or worried when a stock crosses above the 20-day simple moving average?
Here's How to Find Cheap Stocks Under $10 to Buy for December
by Benjamin Rains
Use one of our Zacks screens to find strong, highly-ranked stocks that are trading for under $10 per share to consider buying heading into December and beyond...
Provention (PRVB) Gets FDA Nod for Drug That Delays T1D Onset
by Zacks Equity Research
Following FDA approval, Provention Bio's (PRVB) Tzield is the first disease-modifying therapy in T1D. Tzield can delay the onset of stage 3 T1D in individuals aged eight years and older.
Zacks.com featured highlights MacroGenics, Olink Holding, NerdWallet, LiveRamp and LivePerson
by Zacks Equity Research
MacroGenics, Olink Holding, NerdWallet, LiveRamp and LivePerson have been highlighted in this Screen of The Week article.
Wall Street Analysts Believe MacroGenics (MGNX) Could Rally 123%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 122.6% upside potential for MacroGenics (MGNX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
5 Best Stocks to Invest in for Solid Earnings Acceleration
by Tirthankar Chakraborty
Invest in stocks like MacroGenics (MGNX), NerdWallet (NRDS) & LivePerson (LPSN) at the moment for superb earnings acceleration.
MacroGenics (MGNX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
MacroGenics (MGNX) delivered earnings and revenue surprises of 18.37% and 83.52%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts See a 279% Upside in MacroGenics (MGNX): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 278.9% in MacroGenics (MGNX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Analysts Estimate Zimmer Biomet (ZBH) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Zimmer (ZBH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MacroGenics (MGNX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
MacroGenics (MGNX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Gilead (GILD) Inks Deal for Gene Platform in Blood Cancers
by Zacks Equity Research
Gilead (GILD) signs a license agreement with Refuge Biotechnologies to use the latter's gene expression platform to develop treatments for blood cancers.
Gilead's (GILD) Yescarta Gets EC Nod for New Cancer Indication
by Zacks Equity Research
The European Commission approves Gilead's (GILD) CAR T-cell therapy, Yescarta, for treating adult patients with second-line diffuse large b-cell lymphoma and high-grade b-cell lymphoma.
Wall Street Analysts Predict a 291% Upside in MacroGenics (MGNX): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 291% in MacroGenics (MGNX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
MacroGenics (MGNX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
MacroGenics (MGNX) delivered earnings and revenue surprises of 30.93% and 78.30%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
National Vision (EYE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
National Vision (EYE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate MacroGenics (MGNX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
MacroGenics (MGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LeMaitre Vascular (LMAT) Lags Q2 Earnings Estimates
by Zacks Equity Research
LeMaitre (LMAT) delivered earnings and revenue surprises of -9.38% and 2.05%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
MacroGenics (MGNX) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
MacroGenics (MGNX) delivered earnings and revenue surprises of -28.57% and 35.46%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
MacroGenics (MGNX) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
MacroGenics (MGNX) delivered earnings and revenue surprises of -14.46% and 28.67%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Quidel (QDEL) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Quidel (QDEL) delivered earnings and revenue surprises of 49.08% and 0.29%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate MacroGenics (MGNX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
MacroGenics (MGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MacroGenics (MGNX) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
MacroGenics (MGNX) delivered earnings and revenue surprises of -36.51% and -60.41%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts See a 69% Upside in MacroGenics (MGNX): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 69.5% in MacroGenics (MGNX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Company News for Sep 17, 2021
by Zacks Equity Research
Companies in The News Are: F,WYNN,LVS,MGNX
MacroGenics (MGNX) Stock Jumps 8.9%: Will It Continue to Soar?
by Zacks Equity Research
MacroGenics (MGNX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.